Literature DB >> 20017672

TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer.

Ute Warnecke-Eberz1, Ralf Metzger, Elfriede Bollschweiler, Stephan E Baldus, Rolf P Mueller, Hans P Dienes, Arnulf H Hoelscher, Paul M Schneider.   

Abstract

AIMS: Neoadjuvant radiochemotherapy of locally advanced esophageal cancer is only effective for patients with major histopathological response. A total of 17 genes were selected to predict histopathologic tumor response to chemoradiation (cisplatin, 5-fluorouracil, 36 Gy). MATERIALS &
METHODS: For gene-expression analysis quantitative TaqMan low-density arrays were applied. Expression levels in pretreatment biopsies of 41 patients (cT2-4, Nx, M0) were compared with the degree of histopathologic regression in resected specimens applying univariate, multivariate and artificial neuronal network analyses.
RESULTS: Dihydropyrimidine dehydrogenase was identified as an independent predictor associated with major response (p < 0.002). Multivariate analysis of the marker combination provided response prediction with 75.0% sensitivity, 81.0% specificity and 78.1% accuracy. Artificial neuronal network analysis was the best predictive model for major histopathologic response (80% sensitivity, 90.5% specificity and 85.4% accuracy), representing a clinically practical system.
CONCLUSION: Low-density-array RT-PCR analyzed by artificial neuronal network predicts histopathologic response to neoadjuvant chemoradiation in our patient collective, and could be used to further individualize treatment strategies in esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20017672     DOI: 10.2217/pgs.09.137

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  9 in total

Review 1.  Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher; Matthias Schmidt; Ute Warnecke-Eberz
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

Review 2.  Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.

Authors:  M Gusella; E Pezzolo; Y Modena; C Barile; D Menon; G Crepaldi; F La Russa; A P Fraccon; F Pasini
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

3.  Diagnostic marker signature for esophageal cancer from transcriptome analysis.

Authors:  Ute Warnecke-Eberz; Ralf Metzger; Arnulf H Hölscher; Uta Drebber; Elfriede Bollschweiler
Journal:  Tumour Biol       Date:  2015-12-02

Review 4.  Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review.

Authors:  Chang-Juan Tao; Gang Lin; Ya-Ping Xu; Wei-Min Mao
Journal:  J Cancer       Date:  2015-09-15       Impact factor: 4.207

5.  Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients.

Authors:  Ute Warnecke-Eberz; Patrick Plum; Viola Schweinsberg; Uta Drebber; Christiane J Bruns; Dolores T Müller; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

Review 6.  Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer.

Authors:  Anita Lavery; Richard C Turkington
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-01-08

Review 7.  Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma.

Authors:  William Jiang; Jelske M de Jong; Richard van Hillegersberg; Matthew Read
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

8.  Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.

Authors:  E Gross; C Meul; S Raab; C Propping; S Avril; M Aubele; A Gkazepis; T Schuster; N Grebenchtchikov; M Schmitt; M Kiechle; J Meijer; R Vijzelaar; A Meindl; A B P van Kuilenburg
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

Review 9.  Artificial intelligence-assisted esophageal cancer management: Now and future.

Authors:  Yu-Hang Zhang; Lin-Jie Guo; Xiang-Lei Yuan; Bing Hu
Journal:  World J Gastroenterol       Date:  2020-09-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.